Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2018 - 2021)

Allogene Therapeutics has reported Long-Term Deferred Tax for 2 years, with the latest figure at $224.3 million in Q4 2021.

• Quarterly Long-Term Deferred Tax changed N/A year-over-year to $224.3 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $224.3 million (changed N/A YoY) and the FY2021 annual result came in at $224.3 million, changed N/A from the prior year.
• Long-Term Deferred Tax improved to $224.3 million in Q4 2021 per ALLO's latest filing, from $54.0 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $224.3 million in Q4 2021 and troughed at $54.0 million in Q4 2019.